91 related articles for article (PubMed ID: 22856424)
1. Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential.
Entwistle J; Brown JG; Chooniedass S; Cizeau J; MacDonald GC
Cancer Biother Radiopharm; 2012 Nov; 27(9):582-92. PubMed ID: 22856424
[TBL] [Abstract][Full Text] [Related]
2. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin.
Cizeau J; Grenkow DM; Brown JG; Entwistle J; MacDonald GC
J Immunother; 2009; 32(6):574-84. PubMed ID: 19483652
[TBL] [Abstract][Full Text] [Related]
3. Preclinical assessment of an anti-EpCAM immunotoxin: locoregional delivery provides a safer alternative to systemic administration.
Brown J; Rasamoelisolo M; Spearman M; Bosc D; Cizeau J; Entwistle J; MacDonald GC
Cancer Biother Radiopharm; 2009 Aug; 24(4):477-87. PubMed ID: 19694583
[TBL] [Abstract][Full Text] [Related]
4. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
5. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
[TBL] [Abstract][Full Text] [Related]
7. Construction, expression, and characterization of a recombinant immunotoxin targeting EpCAM.
Lv M; Qiu F; Li T; Sun Y; Zhang C; Zhu P; Qi X; Wan J; Yang K; Zhang K
Mediators Inflamm; 2015; 2015():460264. PubMed ID: 25960617
[TBL] [Abstract][Full Text] [Related]
8. EpCAM-specific vaccine response by modified antigen and chimeric costimulatory molecule in cynomolgus monkeys.
Neighbors M; Apt D; Chang JC; Brinkman A; Sipos-Solman I; Ong R; Leong S; Punnonen J
J Immunother; 2008 Sep; 31(7):644-55. PubMed ID: 18600180
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin.
Andersson Y; Engebraaten O; Juell S; Aamdal S; Brunsvig P; Fodstad Ø; Dueland S
Br J Cancer; 2015 Dec; 113(11):1548-55. PubMed ID: 26554649
[TBL] [Abstract][Full Text] [Related]
10. A Novel Immunotoxin Targeting Epithelial Cell Adhesion Molecule Using Single Domain Antibody Fused to Diphtheria Toxin.
Roshan R; Naderi S; Behdani M; Ahangari Cohan R; Kazemi-Lomedasht F
Mol Biotechnol; 2023 Apr; 65(4):637-644. PubMed ID: 36129635
[TBL] [Abstract][Full Text] [Related]
11. Plant-derived EpCAM antigen induces protective anti-cancer response.
Brodzik R; Spitsin S; Golovkin M; Bandurska K; Portocarrero C; Okulicz M; Steplewski Z; Koprowski H
Cancer Immunol Immunother; 2008 Mar; 57(3):317-23. PubMed ID: 17634938
[TBL] [Abstract][Full Text] [Related]
12. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys.
Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Goldenberg DM
Clin Cancer Res; 2011 May; 17(10):3157-69. PubMed ID: 21372224
[TBL] [Abstract][Full Text] [Related]
13. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution studies of epithelial cell adhesion molecule (EpCAM)-directed monoclonal antibodies in the EpCAM-transgenic mouse tumor model.
Kosterink JG; McLaughlin PM; Lub-de Hooge MN; Hendrikse HH; van Zanten J; van Garderen E; Harmsen MC; de Leij LF
J Immunol; 2007 Jul; 179(2):1362-8. PubMed ID: 17617629
[TBL] [Abstract][Full Text] [Related]
15. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
[TBL] [Abstract][Full Text] [Related]
16. EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein.
Hristodorov D; Amoury M; Mladenov R; Niesen J; Arens K; Berges N; Hein L; Di Fiore S; Pham AT; Huhn M; Helfrich W; Fischer R; Thepen T; Barth S
Mol Cancer Ther; 2014 Sep; 13(9):2194-202. PubMed ID: 24980949
[TBL] [Abstract][Full Text] [Related]
17. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
Burges A; Wimberger P; Kümper C; Gorbounova V; Sommer H; Schmalfeldt B; Pfisterer J; Lichinitser M; Makhson A; Moiseyenko V; Lahr A; Schulze E; Jäger M; Ströhlein MA; Heiss MM; Gottwald T; Lindhofer H; Kimmig R
Clin Cancer Res; 2007 Jul; 13(13):3899-905. PubMed ID: 17606723
[TBL] [Abstract][Full Text] [Related]
18. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M
Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649
[TBL] [Abstract][Full Text] [Related]
19. Generation of an anti-EpCAM antibody and epigenetic regulation of EpCAM in colorectal cancer.
Liao MY; Kuo MY; Lu TY; Wang YP; Wu HC
Int J Oncol; 2015 Apr; 46(4):1788-800. PubMed ID: 25652097
[TBL] [Abstract][Full Text] [Related]
20. Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1).
Woo JH; Bour SH; Dang T; Lee YJ; Park SK; Andreas E; Kang SH; Liu JS; Neville DM; Frankel AE
Cancer Immunol Immunother; 2008 Aug; 57(8):1225-39. PubMed ID: 18256829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
